Project Details
Description
Cardiovascular disease is today the most common cause of death and disability. The main underlying condition is atherosclerosis: plaques of lipids, cells and proteins which are formed in the arterial wall over decades. Atherosclerotic plaques are commonly found in some arteries but only a few will cause acute complications, such as stroke, myocardial infarction or sudden death.
Through our research, we aim to identify clinical methods to detect patients with high-risk plaques, in order to personalize treatment strategies, before they suffer clinical events. We also aim to identify novel biological plaque components and mechanisms, that could be used as therapeutic targets or markers of the disease to prevent complications. A particular interest in the group is also to understand how plaque biology is affected by major clinical risk factors such as diabetes.
Our research strategy combines state of the art imaging, RNA sequencing (bulk, single cell and spatial transcriptomics), C14 dating, genetic and mechanistic studies with follow-up studies in human cardiovascular disease cohorts. Our growing biobank is today one of the largest atherosclerotic biobanks in the world and currently includes over 1500 patients which have undergone surgical removal of atherosclerotic plaques from the carotid or femoral arteries. This biobank makes up the foundation for our unique research, aiming to reduce mortality and morbidity due to atherosclerosis.
The project has received grants from the following foundations (since 2017):
Hjärt-Lungfonden: 1,300,000 SEK per year from 2018 through 2023. 7,800,000 SEK in total.
Skåne University Hospital Foundations: 1,050,000 SEK.
Diabetesfonden:671,000 SEK.
ALF: 1,199,000 SEK per year from 2019 through 2022. 664,000 SEK in 2017 and 740,000 SEK in 2018. 6,200,000 SEK in total.
Strokefonden: 94,000 SEK.
Swedish Research Council: 1,200,000 SEK per year from 2020 through 2023. 700,000 per year from 2017 through 2019. 6,900,000 SEK in total.
Med Tech 4 Health: 1,676,000 SEK.
Mats Paulssons stiftelse: 2,000,000 SEK.
Novo Nordisk A/S: 6,150,000 SEK.
Through our research, we aim to identify clinical methods to detect patients with high-risk plaques, in order to personalize treatment strategies, before they suffer clinical events. We also aim to identify novel biological plaque components and mechanisms, that could be used as therapeutic targets or markers of the disease to prevent complications. A particular interest in the group is also to understand how plaque biology is affected by major clinical risk factors such as diabetes.
Our research strategy combines state of the art imaging, RNA sequencing (bulk, single cell and spatial transcriptomics), C14 dating, genetic and mechanistic studies with follow-up studies in human cardiovascular disease cohorts. Our growing biobank is today one of the largest atherosclerotic biobanks in the world and currently includes over 1500 patients which have undergone surgical removal of atherosclerotic plaques from the carotid or femoral arteries. This biobank makes up the foundation for our unique research, aiming to reduce mortality and morbidity due to atherosclerosis.
The project has received grants from the following foundations (since 2017):
Hjärt-Lungfonden: 1,300,000 SEK per year from 2018 through 2023. 7,800,000 SEK in total.
Skåne University Hospital Foundations: 1,050,000 SEK.
Diabetesfonden:671,000 SEK.
ALF: 1,199,000 SEK per year from 2019 through 2022. 664,000 SEK in 2017 and 740,000 SEK in 2018. 6,200,000 SEK in total.
Strokefonden: 94,000 SEK.
Swedish Research Council: 1,200,000 SEK per year from 2020 through 2023. 700,000 per year from 2017 through 2019. 6,900,000 SEK in total.
Med Tech 4 Health: 1,676,000 SEK.
Mats Paulssons stiftelse: 2,000,000 SEK.
Novo Nordisk A/S: 6,150,000 SEK.
| Status | Active |
|---|---|
| Effective start/end date | 2005/01/01 → … |
Funding
- Leducq Foundation for Cardiovascular Research
- The Swedish Heart Lung Foundation
- Swedish Research Council
- Stiftelsen Ragnhild och Einar Lundströms Minne
- Tore Nilsons Stiftelse för medicinsk forskning
- Skåne university Hospital foundations
- Swedish Society of Medicine
- Novo Nordisk A/S
- Stiftelsen Lars Hiertas minne
UKÄ subject classification
- Cardiac and Cardiovascular Systems